Key result
Targeted genetic testing identifies causal mutations, primarily LDLR, in ~60% of North American FH patients.
Why the study?
Familial hypercholesterolemia is commonly caused by mutations in LDLR, APOB, or PCSK9 genes, but the prevalence of these mutations and clinical differences in mutation-positive versus mutation-negative subjects in North America are not fully characterized.
What is the prevalence of pathogenic mutations in known culprit genes in patients meeting Simon Broome criteria for familial hypercholesterolemia?
Cohort (n=200)
Yes
What is the prevalence of pathogenic mutations in known culprit genes in patients meeting Simon Broome criteria for familial hypercholesterolemia?
Answers are grounded in this paper and cite their sources.
A significant proportion (40%) of North American patients meeting clinical criteria for familial hypercholesterolemia lack mutations in known culprit genes, highlighting the need to identify other genetic and environmental factors.
Background Familial hypercholesterolemia (FH) confers a very high risk of premature cardiovascular disease and is commonly caused by mutations in low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), or proprotein convertase subtilisin/kexin type 9 (PCSK9) and very rarely in LDLR adaptor protein 1 (LDLRAP1) genes. Objective To determine the prevalence of pathogenic mutations in the LDLR, APOB, and PCSK9 in a cohort of subjects who met Simon Broome criteria for FH and compare the clinical characteristics of mutation-positive and mutation-negative subjects. Methods Ninety-three men and 107 women aged 19 to 80 years from lipid clinics in the United States and Canada participated. Demographic and historical data were collected, physical examination performed, and serum lipids/lipoproteins analyzed. Targeted sequencing analyses of LDLR and PCSK9 coding regions and exon 26 of APOB were performed followed by detection of LDLR deletions and duplications. Results Disease-causing LDLR and APOB variants were identified in 114 and 6 subjects, respectively. Of the 58 LDLR variants, 8 were novel mutations. Compared with mutation-positive subjects, mutation-negative subjects were older (mean 49 years vs 57 years, respectively) and had a higher proportion of African Americans (1% vs 12.5%), higher prevalence of hypertension (21% vs 46%), and higher serum triglycerides (median 86 mg/dL vs 122 mg/dL) levels. Conclusions LDLR mutations were the most common cause of heterozygous FH in this North American cohort. A strikingly high proportion of FH subjects (40%) lacked mutations in known culprit genes. Identification of underlying genetic and environmental factors in mutation-negative patients is important to further our understanding of the metabolic basis of FH and other forms of severe hypercholesterolemia.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2019) conducted a cohort in Familial hypercholesterolemia (n=200). Pathogenic mutations in LDLR, APOB, and PCSK9 vs. No mutations in known culprit genes was evaluated on Prevalence of pathogenic mutations in LDLR, APOB, and PCSK9. In a North American cohort of patients with familial hypercholesterolemia, 60% had disease-causing mutations (primarily LDLR), while 40% lacked mutations in known culprit genes.
Synapse has enriched 10 related papers. Consider them for comparative context: